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Abstract
Purpose The aim of this work is to review the lenses,
assessing their advantages and disadvantages. We describe a
total of seven types of intraocular lenses (IOLs) recommended
for age-related macular degeneration (AMD).
Methods We used the PubMed web platform to search for
implantable devices in various stages of AMD. We searched
for both prospective and retrospective studies and also case
reports.
Results Clinical results in AMD patients have been described
for a total of seven types of IOLs recommended for AMD: an
implantable miniature telescope (IMT), IOL-VIP System,
Lipshitz macular implant (LMI), sulcus-implanted Lipshitz
macular implant, LMI-SI, Fresnel Prism Intraocular Lens,
iolAMD and Scharioth Macula Lens.
Conclusions We conclude that to objectively ascertain the ef-
fectiveness and safety of these lenses, further independent
clinical studies with longer follow-up data are necessary prior
to the general use of these optical devices.
Keywords Implantable miniature telescope . IOL-VIP
system . Lipshitz macular implant . Fresnel prism intraocular
lens . iolAMD . Schariothmacula lens
Introduction
Age-related macular degeneration (AMD) is one of the most
disabling diseases for visual quality. Although an estimated
80% of AMD patients have non-neovascular or atrophic
AMD, the neovascular form is responsible for nearly 90% of
the severe central visual acuity loss associated with AMD [1].
The condition in a dry form is caused by aging and thinning of
the tissues of the macula. Exudative macular degeneration
occurs when choroidal neovascularization (CNV) is present
[1, 2].
Central scotomas appear in the final stage of macular de-
generation. This does not usually affect the peripheral vision
[1, 3]. Age-related macular degeneration has been described
as the leading cause of legal blindness, affecting 10–13% of
adults over 65 years of age in North America, Europe,
Australia and, recently, Asia [2].
Visual rehabilitation with low vision magnifiers has been
the principal method for helping these patients, some exam-
ples are: hand/stand magnifiers, spectacles, hand held tele-
scopes, closed circuit televisions, and high-plus spectacles in
conjunction with high-minus contact lenses to create a tele-
scopic effect. Although these tools maybe effective for
correcting overall visual functioning, they have several limi-
tations. They are cumbersome to use and cosmetically burden-
some [4].
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For several years, specially designed intraocular implants
have become a possible and attractive way to circumvent
many of the problems faced in extraocular visual aids. The
aim of this work is to review the lenses assessing their advan-
tages and disadvantages [5].
Materials and methods
We used the PubMed web platform to search for implantable
devices in various stages of AMD. We looked for both pro-
spective and retrospective studies and also case reports. Our
key words were strictly connected to our subject of concern:
iolAMD, Scharioth lens, Fresnel Prism, IOL-VIP System, im-
plantable miniature telescope, Lipshitz macular implant. We
selected English language articles strictly connected with in-
traocular lenses used in diagnosed AMD. Only lenses with
peer reviewed, published clinical outcomes in human patients
affected by AMD were considered for this review.
Results
This article summarizes the mechanism and results for seven
different IOLs designed to help patients with AMD: an im-
plantable miniature telescope (IMT), IOL-VIP System,
Lipshitz macular implant (LMI), sulcus-implanted Lipshitz
macular implant, LMI-SI, Fresnel Prism Intraocular Lens,
iolAMD and SchariothMacula Lens. The summary of clinical
results is presented in Table 1.
Optical fundamentals of IOLs for AMD
The most common approach, used in IMT lenses, the IOL-
VIP System, and iolAMD is a Galilean type telescope. For the
Galilean approach, two optical elements with high positive
and negative power should be used in combination with the
cornea. IMT lenses can achieve higher magnification than
IOL-VIP System and iolAMD because the positive and neg-
ative lenses are embedded in air. This configuration increases
the dioptric power in each of the lenses in an order of magni-
tude that cannot be achieved with lenses embedded in an
aqueous medium. On the other hand, it requires the implanta-
tion of a long tube through a larger corneal incision. The IOL-
VIP System requires implantation of the positive lens in the
anterior chamber and as with the iolAMD there is a version
that incorporates a decentration of one of the IOLs to generate
a displacement of the retinal image from a potentially dam-
aged central retinal area. The iolAMD incorporates asphericity
in the positive lens to gain depth of focus and to be highly
tolerant to small changes in the nominal axial distance be-
tween both lenses. The lenses are smaller and thinner and
the positive optical elements are implanted in the sulcus
[6–9, 13–17].
Another telescope approach is the LMI, based on a
Cassegrain configuration, which uses mirrors instead of
lenses. It can provide high magnification, but due to the so-
phistication of the device it probably requires higher
manufacturing costs, especially compared to a simple silicon
or acrylic IOL. Additionally, the use of small mirrors might
generate the risk of glare effects, due to diffraction and ghost
reflections in the elements that should be further investigated
in clinical trials [10, 11].
The Fresnel Prism Intraocular Lens provides no magnifica-
tion at all. It only displaces the retinal image from a potentially
damaged central macula to a more peripheral healthier area in
the retina. The Fresnel approach (the partition of the optical
surface in Fresnel zones) is necessary here to provide the
required tilt of the image, as the introduction of a direct prism
in the whole surface of the lens would not be possible in
practice (one of the edges of the lens would be too thick). A
potential problem of this approach might be diffraction and
scattered light at the edges of each Fresnel zone. As shown in
Fig. 5, there might be some light that is scattered away from
the focal point, which might be a source of glare [12].
Finally, the approach used in the Scharioth Macula Lens is
based on magnification at closer distances. The closer the
object to the eye, the higher the magnification. In this ap-
proach it needs to be considered that the subject is unable to
accommodate and for that reason it incorporates a +10 D
central area in the lens. Magnification is only achieved when
the object is in a range of 10 to 15 cm from the eye. It provides
no distance vision magnification [18].
Clinical outcomes
Intraocular magnifier telescope (IMT)
It should be emphasized that the short name of this lens is
quite confusing. The BIMT^ abbreviation is commonly used
for all models of the implant. In fact, it should refer to the
original model, which went out of use in 2001. After that,
the production of a Bwide-angle^ model began, sometimes
abbreviated as BWA IMT .^ With high probability we can say
that scientific publications after 2001, despite the abbreviation
IMT, refer precisely to the Bwide-angle^ model, but unfortu-
nately it is unclear. The BWA^ prefix is used for the two
product models available differing in magnification: a wide-
angle 2.2X and wide-angle 2.7X. The first one gives full field
of view of 24° and the second one, 20°. The other features are
the same for both models.
For the purpose of this chapter, we are referring to the
currently used version of the implant.
An implantable miniature telescope (IMT) prosthetic de-
vice was designed specifically for patients with the most
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advanced or end-stage form of AMD. The IMT combined
with the optics of the cornea produces a telephoto effect that
enlarges images in a patient’s central visual field 3×with a 20–
24° field of view projected onto approximately 55° of the
retina. Intended for monocular implantation, the implanted
eye provides central vision, while the other eye remains Bas
is^ to retain peripheral vision, which is important for main-
taining balance and orientation. As it is implanted rather than
being external and hand-held, the IMTallows patients to see in
both dynamic and static situations at near, intermediate, and
distance vision ranges [15, 19–21].
The IMT is a fixed-focus quartz glass lens with wide-angle
micro-optics which is implanted in the capsular bag through a
10–12 mm incision after the natural lens has been removed
(Fig. 1). Larger than most implanted devices, the IMT is a
4.4 mm long telescope contained in a polymethyl methacry-
late (PMMA) carrying device with an overall haptic-to-haptic
diameter of 13.5 mm. Two modified C-loops facilitate in-the-
Table 1 Summary of the clinical data from selected articles
IMT WA IMT IOL-VIP
System
LMI
LMI-SI
Fresnel Prism
Intraocular
Lens
iolAMD Scharioth
Macula
Lens
Number of
cases
reported
3 [6]
40 [7]
217 [5] 40 eyes
of 35
pa-
tients
[8]
6 [9]
3 [10]
3 [11] 3 eyes of 2
patients [12]
18 eyes of 12
patients [13]
8 [14]
Mean
preopera-
tive visual
acuity
0.15 with no external
telescope [6]
UDVA 0.1
UNVA 0.11 [7]
20/80–20/800 [5] CDVA
1.28
Reading
dis-
tance
(cm)
4.44
[8]
DVA 1.47
NVA 24.16 [9]
no data [10]
CDVA 0.12
[11]
CDVA 0.08
CNVA 0.03 or
less [12]
CDVA 0.12
CNVA <0.14
[13]
CDVA
0.05–-
0.4
CNVA @
40 cm
0.18
CNVA @
15 cm
0.3
[14]
Mean
postopera-
tive visual
acuity
0.24 after 18 months [6]
UDVA 0.2
UNVA 0.22 [7]
12 months
post-op mean
3.43 lines im-
provement in
BCDVA [5]
CDVA
0.77
Reading
dis-
tance
(cm)
12.18
[8]
DVA 0.94
NVA 75.00 [9]
No data [10]
CDVA 0.1
[11]
CDVA 0.64
CNVA 0.64
[12]
CDVA 0.20
CNDA 0.21
[13]
UNVA @
15 cm
0.5
[14]
Gains in lines
or letters
No data [6, 7] After 60 months:
2.1 lines
(>75 years
old),
2.7 lines
(younger
patients) [5]
Reading
dis-
tance
gain -
7.66 -
cm [8]
3.66 lines change in ETDRS
score 50.83 [9]
no data [10]
No data,
displace-
ment of the
scotoma
(all
patients)
[11]
No data [12,
13]
CNVA @
40 cm -
4.4
lines
CNVA @
15 cm -
2.1
lines
[14]
Complications Narrow field of view (all
patients) [6]
Pupillary cyclitic
membrane, synechiae,
posterior capsular
opacification, corneal
edema, hyphema,
conjunctivitis, uveitis [7]
Corneal edema
iris damage/
prolapse cap-
sular rupture,
removal of the
device [5]
None [8] Slight glare (all patients);
shadowing of images that
occluded the un-operated
eye (2 patients); adapted
within 3 months of surgery
[9]
No data [10]
Posterior
capsule
opacificati-
on (1 eye)
[11]
Diplopia for
distance
vision (one
patient,
monocular
implanta-
tion) [12]
In 1 eye, an
anterior
sulcus IOL
was replaced
[13]
None [14]
UDVA uncorrected distance visual acuity, UNVA uncorrected near visual acuity, CDVA corrected distance visual acuity, CNVA corrected near visual
acuity, BCDVAbest corrected distance visual acuity, upper index number of reference
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bag fixation. The device weighs 60 mg in aqueous; 115 mg in
air. The lens aperture is 3.2 mm. The IMTextends through the
pupil and remains on average 2.5 mm from the posterior cor-
nea, preventing damage to the endothelium [5, 16, 22, 23].
The US FDA first approved the device in June 2010, orig-
inally restricting implantation to patients older than 75 years
of age. In 2014, the FDA lowered this criterion to 65. Suitable
patients must also be phakic in at least one eye and meet other
vision and eye health criteria [15].
The first systematic clinical report with the first generation
device was published by Alió et al. They performed a multi-
center study in which the IMTwas implanted in 40 eyes of 40
patients with dry-type AMD. Patients were followed up for
12 months. They concluded that the IMT played an important
role in improving near and far visual acuity in patients with
stable dry-type AMD. However, they stressed the problem of
severe visual field restriction and the cumbersome postopera-
tive visual rehabilitation [7].
Due to the optical principle on which this IOL is
based, it was not difficult to observe in the reports that
a main disadvantage of IMT implantation is the con-
fined central visual field to a 20° angle. The IMT is
implanted in one eye only while the other eye is used
to preserve the peripheral visual field, that is why bin-
ocularity is lost with this procedure [7] (Fig. 1).
The IMT is well documented in the literature. Two multi-
year clinical studies have been conducted to evaluate the safe-
ty and efficacy of the telescope implant: the IMT-002 pivotal
safety and efficacy study and the IMT-002-LTM long-term
monitoring safety study [15, 19]. The 2-year, prospective,
28-center IMT-002 pivotal study (n = 217) evaluated the safe-
ty and effectiveness of the IMT for the improvement of visual
acuity in patients with bilateral moderate to profound central
vision impairment (best corrected distance visual acuity
(BCDVA) between 20/80 and 20/800) due to untreatable
end-stage AMD [24]. The IMT improved visual acuity and
quality of life in subjects with end-stage AMD. The primary
effectiveness endpoint, a 2-line or greater gain in either dis-
tance or near best corrected visual acuity (BCVA) at 12months
in at least 50% of study subjects was met and exceeded.
Approximately 90% of patients demonstrated two or more
lines of improvement on the ETDRS visual acuity chart and
67% of patients were able to see three or more lines after the
surgery compared to 13% of fellow eye controls.
At the 12-month mark, an assessment using the National
Eye Institute Visual Functioning Questionnaire-25 (VFQ-25)
demonstrated that the telescope implant significantly im-
proved quality of life in this study population. Not only was
there an improvement in vision-specific subscales, which
would be expected with a doubling of visual acuity achieved
when participants were trained to understand their new vision
post-implantation, but there was also a significant improve-
ment in the psychosocial vision-targeted dependency, mental
health, role difficulties, and social functioning subscales.
Results suggest that patients are less dependent on others, less
worried or frustrated with their visual acuity, less limited in
their activities related to visual acuity, more able to visit
others, and better able to recognize facial expressions [19].
Ocular complications encountered during the studies
included endothelial cell loss, inflammatory/pigment de-
posits, transient cornea edema and IOP elevation.
Regarding concerns about endothelial cell loss, it has
been shown to be consistent with that reported for con-
ventional IOLs [15, 25, 26].
It is also reported that three eyes required explantation of
the lens because of patient dissatisfaction and a conventional
posterior chamber IOL was implanted [7].
Patients participating in the company’s 24-month pivotal
safety and efficacy study, IMT-002, were invited to participate
in the IMT-002-LTM extension study. Patients were followed
for 60months after IMT implantation. Efficacy and safety data
were analyzed for the entire patient population and were then
further stratified by age for two patient cohorts, those aged 65
to 74 (Group 1) and those aged 75 and older (Group 2).
Overall, both groups of patients demonstrated substantial vi-
sual acuity improvement and retention, although outcomes
were somewhat more favorable in the younger patient group.
In Group 1, mean BCDVA improvement from baseline was
3.3 lines at 24 months and 2.7 lines at 60 months. In Group 2,
mean BCDVA improvement from baseline was 3.1 lines at
24 months and 2.1 lines at 60 months. A substantially larger
percentage of patients in Group 1 retained three or more lines
of vision at month 60 than in Group 2 (58% vs. 38%, respec-
tively). Younger patients also had fewer reported adverse
events than their older counterparts. The most frequent
adverse events (AEs) in Group 1 were iris prolapse
(n = 6/70; 8.6%) and iris damage (n = 4/70; 5.7%).
The leading AEs in Group 2 were corneal edema within
the first 30 days after surgery (n = 10/127; 7.9%) and
iris transillumination defects within the first 30 days
after surgery (n = 7/127; 5.5%). Group 2 reported more
AEs in 11 of the 14 reported category events [15].
As described by Joondeph, telescope-implanted eyes may
develop choroidal neovascularization because of the natural
course of age-related macular degeneration, although it is rare
Fig. 1 Manner of action of the Implantable Miniature Telescope (IMT)
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and develops in less than 0.5% of eyes. He describes a tech-
nique in which these patients can be diagnosed via ocular
coherence tomography imaging and treated with intra-vitreal
injection, similar to phakic or pseudophakic eyes. In must be
stressed that the patient’s commitment to the visual rehabilita-
tion to adapt to their new field of vision in one eye combined
with peripheral vision in the other eye is critical for the
success of the telescope implant procedure. Low vision
specialists are an integral part of the procedural team
because they teach patients exercises related to static
and dynamic movement [27].
The diagnosis and management of CNV requires optical
coherence tomography (OCT) imaging of the macula, which
presents several unique challenges to the physicians when
performing it in patients with an IMT. The first obstacle is
due to the IMT itself; it is difficult, if not impossible, to get a
clear view of the macula through the IMT. Fundus photogra-
phy or angiography through the IMT creates a minimized,
distorted image. The second limitation is that patients with
the IMT may be unable to focus on the fixation target during
an OCT session due to the loss of central vision, resulting in
constant scanning or moving of the eye. In addition, the longer
scan time required due to the aforementioned poor fixation
may lead to drying of the corneal surface, further impairing
the view of the fundus [28, 29]. Some of the methods physi-
cians may use to overcome these barriers to capture high-
quality OCT images include lubrication of the ocular surface
with artificial tears, the best possible dilation of the pupils, and
using anatomical landmarks such as the optic nerve to locate
the macular region [30, 31].
Some modifications in certain features of the OCT increase
the likelihood of detecting retinal fluid in eyes with the IMT.
For example in SD-OCT all retinal scans should use the 20°
lens and the fast preset volume scan pattern. Condensing the
area of the preset volume scan pattern overcomes the minimi-
zation effect of the telescope to focus on the macular region
and improves the quality of the image. Changing the number
of sections from 23 to 193 can achieve greater anatomic detail
of the fovea [31].
IOL-VIP system
The IOL-VIP System consists of two IOLs that reproduce an
intraocular Galilean telescope: a high minus-power biconcave
IOL (about 66 diopters D) in the capsular bag acts as the
eyepiece, and a high plus-power biconvex IOL (about 55 D)
in the anterior chamber (AC) acts as the objective (Fig. 2).
Both lenses are made of polymethyl methacrylate, have a
one-piece design, and provide ultraviolet light filtering. The
optic of the two lenses is 5 mm in diameter, with a maximum
axial thickness of 1.5 mm for the AC IOL and peripheral
thickness of 1.5 mm for the in-the-bag IOL; their total length
is 13 mm. The system provides an estimated magnification for
distance of 1.3 [5, 8, 9].
Insertion of the IOL-VIP System is preceded by a standard
phacoemulsification. Due to the thickness of the IOLs, the
surgical protocol recommends a capsulorrhexis with a diame-
ter of at least 6 mm to facilitate the implantation of the in-the-
bag IOL, with the enlargement of the temporal corneal inci-
sion to up to 7 mm [9].
The candidates for IOL-VIP System implantation are se-
lected using software that collects their clinical data. All pa-
tients undergo a 2-week preoperative training (12 30-min
training sessions) and a 3-month postoperative rehabilitation
program (five 30-min training sessions per week for 12weeks)
aimed at training and consolidating the preferred retinal locus
(PRL) [5, 9].
One report described the outcomes observed in forty eyes
of thirty-five consecutive patients with a stable central scoto-
m a d u e t o m a c u l a r d i s e a s e w h o u n d e rw e n t
phacoemulsification cataract surgery with the implant of the
IOL-VIP System [9]. All patients showed an improvement in
visual acuity (VA) due to the surgical and rehabilitative pro-
cedure, confirming or exceeding the preoperative expected
results. Mean postoperative best corrected visual acuity
(BCVA) was 0.77 (logarithm of the minimum angle of reso-
lution), compared to 1.28 preoperatively. The mean postoper-
ative best reading magnification gain was 6.2, and the mean
postoperative reading distance gain was 7.66 cm. It was
highlighted that the IOL-VIP System was subjectively well
tolerated and did not seem to limit the peripheral visual field
or interfere with binocular vision, thus making it suitable for
monocular or binocular implantation. There were no severe
complications intra or postoperatively with the exception of
pupillary block with increased intraocular pressure, promptly
managed by means of neodymium:yttrium–aluminum–garnet
(Nd:YAG) laser iridotomy. Due to this, preoperative
iridotomy was performed in all other cases [9].
Given the size of the two IOLs, there may be concerns
about the space they occupy in the anterior segment of the
eye and their proximity to critical ocular structures such as
the corneal endothelium and iris. It is true that after implanta-
tion there may be a shallow anterior chamber, so an exceed-
ingly low endothelial cell count, and/or guttata are obvious
contraindications. However, 20-month observation showed
Fig. 2 Manner of action of the IOL-VIP System
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that endothelial cell counts had decreased by only 7% at the
end of follow-up [9] (Fig. 2).
Lipshitz macular implant (LMI)
An implant created by Dr. Lipshitz was made in two
versions. The first was the Lipshitz macular implant
(LMI) conventional IOL that incorporates two miniature
mirrors in the Cassegrain telescope configuration, mag-
nifying the reflected image on the retina 2.5 times. The
patient thus sees a magnified central image through the
mirror telescope and a normal non-magnified image
through the periphery of the IOL [10] (Fig. 3).
The overall diameter of the IOL is 13.0mm, and the optic is
6.5 mm. The anterior central mirror is 1.4 mm. The posterior
mirror, which is doughnut shaped and 2.8 mm in diameter, has
a central clear area of 1.4 mm in diameter. The peripheral zone
of the optic is similar to that of a normal IOL in order to
provide undisturbed peripheral vision. The reflecting surfaces
of the LMI are coated with multiple layers of titanium oxide
and silicon dioxide (dielectric coatings), which creates a mir-
ror effect. The mirrors are 1 to 2 mm thick. The entire IOL is
coated with poly-para-xylylenes (Parylene C) to enhance bio-
compatibility. The LMI is placed through a 6.5 mm corneal
tunnel into the capsular bag [10].
It is reported that the LMI was implanted in six worse-
seeing eyes of 6 patients. However only four of the operated
eyes had AMD, two had other macular pathologies. In all
patients visual acuity was worse than 20/200 and it improved
with a 2.5 magnifying external telescope preoperatively.
There were no intraoperative complications. The mean gain
in distance acuity was 3.66 lines ± 1.88 (SD), and the mean
increase in the Early Treatment Diabetic Retinopathy Study
(ETDRS) score for near acuity was 50.83 ± 9.15 logMAR.
The best corrected distance acuity and near acuity improved
significantly (both P = .014) [10].
The younger and improved version of the LMI has the
same function - to magnify the central image while the periph-
eral field remains normal. The main difference between the
two lenses is that the newer LMI-SI is the equivalent of two
IOLs and is well supported by placement within the capsular
bag alone. The LMI-SI is a non-foldable one-piece IOL posi-
tioned in the sulcus over a regular bag-implanted IOL. It is
5 mm or 6 mm in diameter, and it contains loops that have a
similar configuration to a regular IOL (loop diameter is
13.5 mm). However, the LMI-SI is thicker, with a central
thickness of 1.25 mm. After standard phacoemulsification,
the incision is then enlarged to 5 to 5.5 mm. After implantation
a peripheral iridectomy is then performed surgically [11].
According to a publication, three patients were operated on
using the LMI-SI IOL. The inclusion criteria for a pilot trial
included patients with bilateral AMD (dry type, wet type, or
scar stage) or other similar macular lesions in which visual
acuity ranged between 20/80 and 20/800 in each eye and
improved for distance and/or near when tested with 2.5 mag-
nification using an external telescope. Postoperative visual
acuity of these patients is not reported in the publication [11].
The LMI and LMI-SI provide magnified central images up
to 2.5 times while maintaining the normal peripheral vision
through the peripheral portion of the lens. Due to this, both can
be implanted in both eyes of a patient [10, 11] (Fig. 3).
Fresnel Prism Intraocular Lens
The in-the-bag Fresnel Prism Intraocular Lens is a non-
foldable implant made of polymethyl methacrylate (PMMA)
(Fig. 4). It was created for optical displacement of the central
scotoma caused by AMD, to avoid moving the retina with all
the risks involved in macular translocation surgery [12].
For implantation, standard phacoemulsification is per-
formed and then a scleral tunnel incision is created for inser-
tion. The prototypes of the device have a single optical power
(+20.0 diopters) for aphakic correction, with a Fresnel prism
IOL fashioned on the posterior surface of the optic producing
a fixed 6° deviation, which gives a retinal image displacement
of 1.8 mm (thus describing a circular area of 3.6 mm diameter)
for a 23.1 mm average eye [12].
The only publication we found on the Fresnel Prism
Intraocular Lens reports that the implant was fixed unilaterally
in three eyes of three patients with bilateral advanced
nonexudative AMD. The inclusion criteria were bilateral
AMD, a decimal corrected distance visual acuity of 0.1 or
worse in the better eye (eye for the IOL implantation), and a
lesion diameter no larger than 3.3 mm. Preoperatively, direc-
tion of the image deviation was identified using a handheld
visuoscope to identify the preferred retinal locus for
extrafoveal fixation. The uncorrected distance visual acuity
(UDVA) of all patients was 0.05 and corrected distance visual
acuity (CVDA) was between 0.05 and 0.16. After the surgery,
no objective testing of scotoma displacement was performed;
however, all patients reported displacement of the scotoma
peripheral to their central field of vision and noted that the
scotoma was less bothersome. No patient described diplopia.
One patient reported that she preferred her un-operated eye to
the eye with the prismatic IOL, despite having a less obvious
eccentric scotoma in the operated eye. This was because she
Fig. 3 Manner of action of the Lipshitz macular implant (LMI)
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perceived the image to be clearer in the un-operated eye.
Postoperatively, UDVA in the three eyes was between 0.05
and 0.10 and CVDA 0.05–0.16 [12].
Oculomotor functions and fixation stability control
change in relation to the new preferred retinal fixation
locus. The newly formed oculomotor functions can be
improved by exercising or by spectacle prismatic image
relocation [12] (Fig. 4).
iolAMD
The iolAMD is the most recent type of hydrophobic acrylic
device to improve vision for people suffering fromAMD. The
implant is based on a Galilean telescope using two lenses
manufactured so that they can be injected with a standard soft
tip cartridge and injector system for 3.0-mm incision size
(Fig. 5). After implantation, both implants allow a magnifica-
tion of the image and distribution of the retinal picture 3° apart
from the fovea due to the slightly intended decentration of the
sulcus implanted IOL (0.85 mm). The capsular bag positioned
IOL (IOL 2) is a high-minus-power lens (−49 diopters [D])
with a 4.0-mm optic and an overall length of 11.0 mm. The
plate haptic is symmetrical and vaulted posteriorly approxi-
mately 15°. The sulcus-positioned IOL (IOL 1) is a high-plus-
power lens (+63 D), and the 5.0-mm hyper-aspheric-optic is
slightly de-centered on the plate haptic. The overall diameter
is 11.75 to 12.0 mm and the haptic is bent anteriorly to en-
hance the recommended distance between the optics of 2 mm
after implantation [13, 14, 17].
It is reported that three eyes of two patients with visually
significant cataract and intermediate dry macular degeneration
with drusen were operated by phacoemulsification with inser-
tion of the iolAMD. Preoperative corrected distance visual
acuity ranged from 0.03 to 0.16 and corrected near visual
acuity was 0.03 or less. No surgeries had any complications.
There was no rise in intraocular pressure or iris-related prob-
lems such as shaving of pigment or pupillary block. The pa-
tient with bilateral implantation perceived no double vision
because the decentration axis in both eyes was vertical. The
other patient with singular implantation recognized an in-
crease in visual acuity but complained about diplopia in a
vertical direction (which could be solved by prismatic specta-
cle correction). All lenses were placed on a vertical axis and
the IOL implantations were achieved safely and were stable
during the 3-month follow-up. No postoperative rotation was
necessary. Two months after surgery, corrected distance and
near visual acuities increased to levels between 0.5 and 0.8
(uncorrected distance visual acuity was 0.3 to 0.6; uncorrected
near visual acuity was 0.1 to 0.8) [17].
In another study, 18 eyes of 12 patients had the
iolAMD implanted. Inclusion criteria included bilateral
intermediate or advanced dry AMD with central scoto-
mata; minimal cataract or pseudophakia; Snellen
corrected distance visual acuity (CDVA) of less than
0.25, improvement on simulation with the new inject-
able telescopic IOL (CDVA or subjective improve-
ment). All surgeries were uneventful except in one
eye in which the high-plus IOL was vaulting anteriorly,
causing a reduction in the quality of vision. This high-
plus IOL was replaced with a smaller-diameter IOL,
after which there were no short to medium term sequel-
ae . A precau t iona ry in t r aope ra t ive pe r iphe ra l
iridectomy was performed in nine eyes (including the
eye of patient 11 in which the high-plus IOL was re-
placed). In eight eyes, a single 10-0 nylon suture was
used to secure the wound as a precaution; the suture
was removed 1 month after surgery. There was no dif-
ference between the mean preoperative and postopera-
tive intraocular pressure. The mean endothelial cell
density was reduced by 18%. The mean decimal
CDVA improved from 0.12 preoperatively to 0.20 at
4 months, a 67% gain [14].
The only noticeable disadvantage of this system is that
there are no power ranges available, limiting this technology
to eyes with an axial length of 21 to 23 mm with a resulting
power of 21 D. The IOL power cannot currently be adapted
perfectly to patient anatomy [17] (Fig. 5).
Scharioth Macula Lens
The Scharioth Macula Lens is a one-piece foldable intraocular
hydrophilic acrylic lens with a central magnifying portion im-
planted in the ciliary sulcus of pseudophakic eyes, which im-
proves near vision in patients with AMD (Fig. 6). The overall
diameter of the IOL is 13.0 mm with four symmetric haptics.
It has a central portion of 1.5 mm diameter with an addition of
+10.0 Dsph and neutral remaining optical zone [18].
Fig. 4 Manner of action of the Fresnel Prism Intraocular Lens Fig. 5 Manner of action of the IOL AMD
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The IOL can be implanted simultaneously during uncom-
plicated standard phacoemulsification with in-the-bag poste-
rior chamber IOL (PC IOL) implantation or years after cataract
surgery, making it unique among other IOLs implanted only
during a procedure to remove a clouded lens. Another excep-
tional feature of this device is the smallest incision required for
implantation -2.2 mm. The macular add-on IOL does not affect
the peripheral vision and does not reduce binocularity at normal
reading distance. Binocularity is reduced only at a reading dis-
tance of 15 cm. At this distance, the image of the other eye will
be blurry and will not cause diplopia [18].
A minimum corrected distance visual acuity (CDVA)
of 0.1 is recommended to achieve sufficient results.
Preoperative testing of corrected near visual acuity
(CNVA) with +2.5 D correction at 40 cm versus +6.0
D correction at 15 cm provides valid information about
the potential of the macular add-on IOL; if CNVA is
better at 15 cm and the patient is motivated, he or she
might be a good candidate for Scharioth Macula Lens
implantation. Possible contraindications to the implanta-
tion of the macular add-on IOL are: complicated cata-
ract surgery (e.g., aphakia, sulcus implanted posterior
capsule IOL), excessive zonular weakness (e.g., exces-
sive pseudoexfoliation syndrome, zonular dialysis, pseu-
do-phacodonesis), excessive secondary cataract, chronic
uveitis, active rubeosis iridis, central corneal opacities,
and inability to understand the principle of this implant
(reduced reading distance, maximum magnification)
[18].
It is reported that the macular add-on IOL was implanted in
the better seeing eye in eight patients. The preoperative CDVA
in the patients was between 0.05 and 0.4. No intraoperative or
postoperative complications occurred. In all patients but one,
the uncorrected near visual acuity (UNVA) at 15 cm and
CNVA improved. The patient without improvement had a
large area of retinal pigment epithelial atrophy of the posterior
pole and a preoperative CDVA of 0.05. Excluding the eye
with exudative AMD, the results were: CNVA improved
by 5.0 lines with the macular add-on IOL at 15 cm
versus with +2.5 D correction at 40 cm; it improved
by 2.4 lines with the macular add-on IOL at 15 cm
versus with +6.0 D correction at 15 cm. No patient
had a postoperative decrease in CDVA [18] (Fig. 6).
Discussion
Limitations and complications of IOLs for AMD
Incision
The first striking advantage of some of the IOL implantation is
that it is a simple procedure that can be performed by all
surgeons trained in phacoemulsification surgery. Devices like
the Scharioth Macula Lens or the iolAMD need incisions no
wider than 3.0 mm, while the IMT needs 10–12mm incisions.
The large incision could cause increased corneal astigmatism
and the risk of further complications [3]. In the size of incision
it is decisive whether the lens is foldable and this determines
the material of which it is made - both the Scharioth Macula
Lens and the iolAMD are acrylic [17, 18].
Pseudophakic eye
Since most lenses or their parts are implanted into a capsular
bag, the result is that they are not appropriate for
pseudophakic patients. The only two implants, which seem
to meet these criteria are the Scharioth Macula Lens and the
LMI-SI; the macular add-ons to a standard IOL have the ad-
vantage that they can be easily implanted in the ciliary sulcus
years after cataract surgery without the need to explant the in-
the-bag IOL or directly after standard phacoemulsification
with regular bag-implanted IOL [11, 18].
Compulsory iridotomy/iridectomy
In some cases during the days after surgery a pupillary block
developed with increased intraocular pressure and a pre- or
intraoperative peripheral iridotomy/ iridectomy should be per-
formedwith the implantation of the IOL-VIP System, the IMT
and the LMI-SI [9, 11, 15]. In the latter, Nd:YAG laser
iridotomy is not recommended [11].
Capsulotomy
Treatment with neodymium:YAG laser is possible in such
cases, but the laser beam should be directed through the clear
part of the haptic and not the glass optic in the case of the IMT.
The posterior part of the IMT presses against the posterior
capsule, decreasing the incidence of posterior capsule
opacification [7].
Fundoscopy
An important drawback of some types of lenses such as the
IMT is that fundus examination is difficult or impossible.
Although the IMT allows fundoscopy, the magnification is
not sufficient to evaluate microscopic changes in the fovea
Fig. 6 Manner of action of the Scharioth Macula Lens
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(eg. progression of AMD) or to detect possible postoperative
posterior segment complications of cataract surgery such as
cystoid macular edema or retinal detachment. In the case of a
sudden and profound decrease in visual acuity, only ultraso-
nography provides clues to the cause [16].
In addition, the LMI shows difficulty in seeing the ora
serrata due to glare. A good central fundus view is possible
around the mirrors but fundus photographs taken from the
center of the lens for patients with implanted LMI had reflec-
tions from the posterior mirror [10].
Rehabilitation
One of the patients’ expectations associated to lens implanta-
tion is immediate improvement of vision and a quick return to
life as prior to surgery. Unfortunately, lenses such as the IOL-
VIP System require complicated visual rehabilitation. There is
a special IOL-VIP software which designs the rehabilitation
strategies based on preoperative and postoperative training of
the preferred retinal locus. All patients undergo 2 weeks of
preoperative training (12 30-min training sessions) and a 3-
month postoperative rehabilitation program (5 30-min training
sessions per week for 12 weeks) aimed at training and consol-
idating preferred retinal locus. Cases of unstable and periph-
eral preferred retinal locus have been reported with large
search movements that did not change with the rehabilitation
training [9].
Some authors also report that patients after IMT implanta-
tion require intensive training postoperatively and it takes 3–
6 months, but there is no information about the type of this
rehabilitation. It should be performed by trained low vision
specialists [7, 15, 16].
Visual field
The serious drawback with some of the lenses like the IMT, is
that magnification at both long and short distances is achieved
but at the expense of a reduction in the visual field and depth
of focus [13, 17]. Thus, bilateral implantation is not possible.
The device is implanted in one eye only, leaving the fellow
eye to compensate for peripheral vision [9, 15].
On the contrary, macular add-on IOLs do not affect the
peripheral vision and do not reduce binocularity at normal
reading distance [18].
Conclusions
In our opinion, there is no single ideal lens for use in existing
AMD without drawbacks. The outcomes reported so far are
variable and most probably have only been focused on short-
term outcomes. The main problems found in the use of this
technology are the strict patient selection criteria required to
avoid quick evaluative forms of AMD and the need to choose
eyes with a potential for visual rehabilitation. It is very impor-
tant to emphasize that these patients need visual rehabilitation
programs and that much of the success will depend on the
commitment and dedication of the patient towards these pro-
grams. An important commercial bias may be present, how-
ever, in the reports of some of the iolAMD models due to a
possible conflict of interest because of financial relations with
the companies producing these lenses or the owners of patent
rights. We may conclude that to objectively ascertain the ef-
fectiveness and safety of these lenses, further independent
clinical studies with longer follow up data are necessary prior
to the general use of these optical devices.
All figures are in the same scale. Axial and transversal
distances of the devices are the ones provided by the manu-
facturers. The lens capsule is 4 mm length, used for reference
here. The model eye used here had a length of 23.5 mm.
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